| Key TakeawaysOzempic (semaglutide) is a once-weekly injectable medicine approved in India by CDSCO for managing type 2 diabetes in adults.It works by mimicking a gut hormone called GLP-1 to lower blood sugar, slow digestion, and reduce appetite.It is not a weight-loss drug by CDSCO approval in India. Any use beyond type 2 diabetes management requires careful medical evaluation and prescription.Clinical trials show it may reduce HbA1c levels by 1.4% to 1.8% and lower the risk of major cardiovascular events by up to 26% in those with established heart disease.Always consult a qualified endocrinologist or diabetologist before considering this medication. |
India now has 101 million people living with type 2 diabetes, according to the ICMR-INDIAB national cross-sectional study (Lancet Diabetes Endocrinol, 2023).
If you or someone you know has been told about Ozempic recently, this guide walks you through exactly what it is, how it works, who it is for, and what to expect.
1. What Is Ozempic — And Why Is Everyone Talking About It?
Ozempic is the brand name for semaglutide (the active ingredient in Ozempic), a prescription injectable medicine developed by Danish pharmaceutical company Novo Nordisk. It belongs to a class of drugs called GLP-1 receptor agonists.
It was first approved by the US Food and Drug Administration (FDA) in December 2017 for adults with type 2 diabetes.
In India, the Central Drugs Standard Control Organisation (CDSCO) granted approval to Ozempic for type 2 diabetes management in late 2025.
The global conversation around Ozempic expanded rapidly when clinical studies began showing meaningful body weight reductions as a secondary effect in people with diabetes. This is why it has entered mainstream awareness far beyond the diabetes community.
Important distinction: In India, Ozempic carries a CDSCO-approved indication specifically for type 2 diabetes management.
Its separate formulation for obesity treatment — Wegovy (higher-dose semaglutide) — has not been independently approved in India as of May 2026. Any use of Ozempic outside its approved indication requires careful medical evaluation.
| Brand Name | Active Ingredient | Indication | Route | Frequency |
|---|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes (India CDSCO-approved) | Subcutaneous injection | Once weekly |
| Wegovy | Semaglutide (higher dose) | Chronic weight management (not independently approved in India as of 2026) | Subcutaneous injection | Once weekly |
| Rybelsus | Semaglutide | Type 2 diabetes | Oral tablet | Once daily |
Sources: NCBI StatPearls: Semaglutide; FDA Prescribing Information, Ozempic 2025
2. How Does Ozempic Actually Work Inside the Body?
Semaglutide shares a 94% structural similarity with the naturally occurring human hormone GLP-1 (glucagon-like peptide-1), according to NCBI StatPearls. GLP-1 is secreted by cells in the gut after a meal.
When you inject Ozempic, it activates GLP-1 receptors in three key locations: the gastrointestinal tract, the pancreas, and the brain.
What Happens at Each Site
| Location | What Semaglutide Does | Effect You Notice |
|---|---|---|
| Pancreas | Stimulates insulin release when blood sugar is high; suppresses glucagon (the hormone that raises blood sugar) | Blood glucose stays in a healthier range after meals |
| Stomach and gut | Slows gastric emptying — food leaves the stomach more slowly | Feeling full for longer; reduced appetite |
| Brain | Acts on appetite-regulating centres in the hypothalamus | Lower drive to eat; reduced food cravings |
A key safety advantage is that the insulin-stimulating effect is glucose-dependent. Ozempic only triggers insulin release when blood sugar is actually elevated.
This sharply reduces the risk of hypoglycemia (dangerously low blood sugar) compared to older diabetes drugs like sulfonylureas. This mechanism is well-documented across the SUSTAIN clinical trial program, reviewed in the Frontiers in Endocrinology (PMC, 2021).
3. What Does the Clinical Evidence Show?
Ozempic has one of the most extensively studied profiles of any diabetes medication on the market. The landmark SUSTAIN clinical trial program enrolled thousands of patients across multiple countries. Here is a summary of what those trials found.
| Trial | What It Compared | Key Finding |
|---|---|---|
| SUSTAIN 1-5 (PMC, 2018) | Semaglutide 0.5mg and 1mg vs placebo and active comparators | HbA1c reduced by 1.4% to 1.8%; weight loss of 2.3 to 6.3 kg |
| SUSTAIN 6 (AJMC, 2021) | Semaglutide vs placebo in patients with high cardiovascular risk | 26% reduction in major cardiovascular events (heart attack, stroke, CV death) |
| FLOW Trial, NEJM 2024 | Semaglutide 1mg vs placebo in type 2 diabetes + chronic kidney disease | 24% reduction in kidney disease progression; 20% lower all-cause mortality |
| SUSTAIN 3 (PMC, 2018) | Semaglutide 1mg vs exenatide 2mg | HbA1c fell 1.5% with semaglutide vs 0.9% with exenatide; weight loss 5.6 kg vs 1.9 kg |
The FLOW trial, published in the New England Journal of Medicine (May 2024), was stopped early on the recommendation of an independent data monitoring committee because the evidence of benefit was so clear. The trial enrolled 3,533 people across 28 countries.
4. Who Is Ozempic For in India?
Ozempic is a prescription medication. A doctor determines whether you are a suitable candidate based on a full clinical evaluation. The following is a general overview, not a substitute for medical advice.
Patients Who May Be Considered
- Adults with a confirmed diagnosis of type 2 diabetes mellitus whose blood sugar is inadequately controlled with diet, exercise, or existing oral medications.
- Adults with type 2 diabetes who also have established cardiovascular disease (history of heart attack, stroke, or peripheral artery disease), given the SUSTAIN-6 cardiovascular outcomes data.
- Adults with type 2 diabetes and chronic kidney disease, following the 2024 FDA approval based on the FLOW trial results (published in NEJM, 2024).
Outcomes are strongly shaped by daily habits. Guidance on what to eat on Ozempic and how to structure exercise on Ozempic can meaningfully reduce side effects and protect lean mass during treatment.
Who Should Not Use Ozempic
| Contraindication or Caution | Why It Matters |
|---|---|
| Personal or family history of medullary thyroid carcinoma (MTC) | Boxed warning on the label; semaglutide caused thyroid C-cell tumors in rodent studies. Human relevance is not confirmed but risk cannot be excluded. |
| Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) | Same thyroid tumour concern as above. |
| Personal history of pancreatitis | Acute pancreatitis has been observed in patients on GLP-1 receptor agonists. A prescribing doctor may choose an alternative. |
| Type 1 diabetes | Ozempic is not indicated for type 1 diabetes. |
| Pregnancy or planned pregnancy | Discontinue at least 2 months before a planned pregnancy due to long washout. Limited human pregnancy safety data. |
| Severe gastroparesis | Ozempic slows gastric emptying, which can worsen this condition. |
| Allergy to semaglutide | Known hypersensitivity is an absolute contraindication. |
Sources: FDA Prescribing Information, Ozempic 2025; Novo Nordisk: Ozempic Safety Information
5. How Is Ozempic Taken? The Dosing Schedule Explained
Ozempic is self-injected once a week using a prefilled disposable pen, under the skin of the abdomen, thigh, or upper arm. It can be taken at any time of day, with or without food.
Dosing follows a gradual escalation schedule. This approach is intentional: it gives the body time to adjust and minimises gastrointestinal side effects.
| Period | Dose | Purpose |
|---|---|---|
| Weeks 1-4 | 0.25 mg once weekly | Initiation dose only. Not therapeutic. Allows the body to adjust. |
| Weeks 5 onwards | 0.5 mg once weekly | First maintenance dose. Blood sugar control begins. |
| After 4+ weeks at 0.5 mg (if needed) | 1 mg once weekly | Increased if additional glycaemic control is required. |
| After 4+ weeks at 1 mg (if needed) | 2 mg once weekly | Maximum recommended dose. Decided by prescribing doctor. |
The maximum recommended dose is 2 mg once weekly. Not everyone needs to reach the maximum dose. Your prescriber will stop escalation at the dose that effectively controls your blood sugar.
For patients who also have chronic kidney disease, the recommended maintenance dose is typically 1 mg once weekly, per the FDA prescribing guidance.
Source: FDA Ozempic Prescribing Information, 2025; Ozempic Dosing Guide, Healthline
6. What Side Effects Should You Know About?
All medicines carry a risk of side effects. With Ozempic, the most common ones are gastrointestinal and tend to be most pronounced in the early weeks of treatment, particularly during dose escalation.
Common Side Effects (Reported in Clinical Trials)
| Side Effect | How Common | What to Do |
|---|---|---|
| Nausea | Very common, especially early on | Eat smaller meals; avoid high-fat foods; usually improves within a few weeks |
| Vomiting | Common | Stay hydrated; contact your doctor if persistent or severe |
| Diarrhoea or constipation | Common | Increase fluid and fibre intake; consult your doctor if it persists |
| Abdominal discomfort | Common | Monitor for severe or worsening pain — see serious side effects below |
| Decreased appetite | Common | This is partly the intended mechanism; not usually a concern |
| Fatigue | Less common | Monitor; report if it significantly affects daily function |
A separate cosmetic concern reported with rapid weight reduction on semaglutide is Ozempic face — a hollowed, gaunt appearance caused by loss of facial fat. It is not dangerous but can affect how people feel about their appearance during treatment.
Serious Side Effects — Seek Medical Attention Immediately
- Acute pancreatitis: Persistent, severe abdominal pain that may radiate to the back, with or without vomiting. Stop Ozempic and seek medical attention immediately. Reviewed in NCBI PMC: Off-label Ozempic and Pancreatitis, 2025.
- Thyroid tumours: Swelling or lump in the neck, hoarseness, difficulty swallowing, or shortness of breath. The FDA boxed warning notes that semaglutide caused thyroid C-cell tumours in rodent studies; human relevance is unknown.
- Hypoglycaemia: Especially if combined with insulin or sulfonylureas. Signs include dizziness, sweating, shakiness, and confusion.
- Worsening kidney function: Can occur in association with dehydration from vomiting or diarrhoea. Stay well hydrated.
- Vision changes: Notify your doctor of any new or worsening vision problems, particularly in patients with existing diabetic retinopathy.
- Surgical or procedural risk: Ozempic slows gastric emptying. If you have a scheduled procedure under anaesthesia, inform your surgical team.
Sources: Novo Nordisk: Ozempic Side Effects; FDA Prescribing Information, 2025
7. What Does Ozempic’s Arrival Mean for India Specifically?
India carries the second-largest diabetes burden globally. The ICMR-INDIAB study (Lancet Diabetes Endocrinol, 2023) found that India has 101 million people living with diabetes.
Prevalence in urban areas is significantly higher — the ICMR-INDIAB study on 15 Indian states (Lancet, 2017) found diabetes prevalence in urban areas to be 11.2% versus 5.2% in rural areas.
This urban-rural gap reflects the lifestyle realities that most city-dwellers are familiar with: sedentary desk work, longer commutes, irregular eating patterns, high-carbohydrate food environments, and chronic stress. These are the same conditions that drive metabolic disease globally.
Additionally, Indians are known to develop type 2 diabetes at lower BMI values than Western populations, partly due to a tendency toward higher visceral fat even at normal weight.
This means the effective threshold for intervention discussions may come earlier in the Indian clinical context.
Availability in India
As of late 2025, CDSCO has officially approved Ozempic for type 2 diabetes management in adults.
According to Tata 1mg (October 2025), Novo Nordisk has received the regulatory green light, with market launch details and pricing to be announced formally at the time of release.
Ozempic is available by prescription only through authorised pharmacies. Counterfeit versions have been reported in international markets. Obtain this medication exclusively through a verified prescription from a registered healthcare provider and a licensed pharmacy.
Note: Insurance coverage for Ozempic in India is limited at this time. Most insurance plans do not cover GLP-1 medications unless specifically justified for diabetes management.
Confirm with your insurer and prescribing physician.
8. How Does Ozempic Compare to Other Diabetes Medications?
Ozempic is not the first-line medication for type 2 diabetes. Most clinical guidelines — including those from endocrinology bodies — start with metformin and lifestyle modification.
Ozempic is typically considered as an add-on or second-line option. Here is how it generally compares.
| Medication | Class | HbA1c Reduction | Weight Effect | Key Advantage |
|---|---|---|---|---|
| Metformin | Biguanide | ~1.0%-1.5% | Neutral or modest loss | Cheapest; well-established safety profile; first-line standard of care |
| Glipizide / Glimepiride (sulfonylureas) | Sulfonylurea | ~1.0%-1.5% | Weight gain common | Inexpensive; widely available in India |
| Sitagliptin / Vildagliptin (DPP-4 inhibitors) | DPP-4 inhibitor | ~0.5%-1.0% | Neutral | Oral; well-tolerated; no weight gain |
| Dapagliflozin / Empagliflozin (SGLT2 inhibitors) | SGLT2 inhibitor | ~0.5%-1.0% | Modest loss | Added heart and kidney benefits; once-daily oral |
| Ozempic (semaglutide) | GLP-1 agonist | 1.4%-1.8% | Meaningful reduction | Cardiovascular and kidney outcome benefits; once-weekly injection |
HbA1c reduction comparisons are adapted from the SUSTAIN clinical trial program (PMC, 2018 and 2020).
The choice of medication always depends on individual clinical profile, comorbidities, tolerability, and doctor recommendation.
| The Bottom LineOzempic (semaglutide) is a weekly injectable diabetes medication now approved in India for adults with type 2 diabetes. It works by mimicking the GLP-1 hormone to lower blood sugar, reduce appetite, and slow digestion. Clinical trials show it can reduce HbA1c by 1.4% to 1.8% and meaningfully lower the risk of heart attacks and kidney disease progression in high-risk patients. It is not a lifestyle shortcut and it is not suitable for everyone. If you have type 2 diabetes and are curious about whether it may be right for you, the next step is a conversation with a qualified endocrinologist or diabetologist who can evaluate your full clinical picture. |
Frequently Asked Questions
Is Ozempic approved in India?
Yes. CDSCO approved Ozempic (semaglutide) by Novo Nordisk for use in adults with type 2 diabetes in India in late 2025.
It is available by prescription only through authorised pharmacies. Formal market launch details including availability timelines were to be announced at the time of product release, per Tata 1mg (October 2025).
Can Ozempic be used for weight loss in India?
Ozempic is CDSCO-approved in India specifically for type 2 diabetes management, not as a standalone weight-loss medication.
While weight reduction has been observed as a secondary effect in clinical trials, prescribing Ozempic purely for obesity without diabetes requires careful medical evaluation by a qualified physician.
Wegovy — a higher-dose semaglutide formulation approved specifically for chronic weight management in some countries — has not been independently approved in India as of May 2026.
How often is Ozempic injected?
Ozempic is injected once a week, on the same day each week, at any time of day, with or without food.
It is given as a subcutaneous injection under the skin of the abdomen, thigh, or upper arm using a prefilled disposable pen.
Per FDA prescribing guidance, the starting dose is 0.25 mg for the first 4 weeks, which is an initiation dose only and then increases gradually.
Is Ozempic safe for the kidneys?
The FLOW trial, published in the New England Journal of Medicine (2024), found that semaglutide 1 mg reduced the risk of major kidney events by 24% and all-cause mortality by 20% in people with type 2 diabetes and chronic kidney disease.
Based on these results, the FDA approved an additional indication for Ozempic in January 2025. However, dehydration from nausea or vomiting can transiently worsen kidney function. Staying well hydrated is important.
Who should not take Ozempic?
Ozempic should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or a known allergy to semaglutide.
It is not indicated for type 1 diabetes. People with a history of pancreatitis, severe gastroparesis, or those who are pregnant or planning pregnancy should discuss alternatives with their doctor.
A full contraindication list is available in the FDA prescribing information.
Does Ozempic cause low blood sugar?
Ozempic rarely causes hypoglycaemia on its own because its insulin-stimulating effect is glucose-dependent.
However, the risk increases meaningfully when Ozempic is combined with insulin or sulfonylureas (such as glimepiride or glipizide).
In those cases, your doctor may reduce the dose of the other medication. Signs of low blood sugar include dizziness, sweating, shakiness, and confusion.
